Why the FOCUS-2 trial matters for Axsome Therapeutics stock

Axsome Therapeutics (AXSM) is attracting attention after dosing the first patient in its FOCUS-2 Phase 3 trial of solriamfetol in children with ADHD, extending its late stage clinical program into pediatrics.

The FOCUS-2 study follows a randomized, double blind, placebo controlled design across multiple centers. It targets children aged 6 to under 12 who are diagnosed with ADHD and treated over a 6 week period.

Roughly 468 patients are set to be randomized equally across two solriamfetol dose arms and a placebo arm. The main outcome measure is the change in ADHD Rating Scale ADHD RS 5 total score from baseline to week six.

For anyone tracking Axsome Therapeutics stock, this new trial sits alongside the company’s FOCUS-3 Phase 3 study in adolescents. Together they form a coordinated effort to assess solriamfetol across a broad pediatric ADHD population.

Solriamfetol is already approved as Sunosi for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea. It is being developed by Axsome for several central nervous system indications beyond ADHD, including MDD with excessive daytime sleepiness, binge eating disorder, and excessive sleepiness tied to shift work disorder.

This broader program means investor interest centers not only on whether FOCUS-2 meets its clinical endpoints, but also on how any future ADHD data might fit into Axsome Therapeutics current commercial portfolio and late stage pipeline.

Axsome Therapeutics stock has been volatile in the short term, with the share price down 1.68% over the last day but up 4.44% over 30 days and 37.43% year to date. The 1 year total shareholder return of 118.58% and 5 year total shareholder return of 332.19% highlight strong longer term momentum as investors weigh new ADHD trial progress alongside recent index moves into the Russell 1000 and Midcap cohorts.

If you are looking for more ideas in a similar space, you can use this momentum as a cue to scan other healthcare-focused AI opportunities through our dedicated screener for 40 healthcare AI stocks

After a strong run and a richer pipeline story around Auvelity and solriamfetol, Axsome Therapeutics now sits at about $245 a share. Does the current setup still leave the risk reward balance tilted toward buyers?

Most Popular Narrative: 11.2% Undervalued

Based on the most followed narrative, Axsome Therapeutics is priced below an estimated fair value of $276.47, compared with the last close at $245.57. This puts extra focus on how its CNS pipeline and new indications are modeled.

The company is advancing multiple late stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Curious what growth path has to play out for that gap to close? Revenue expansion, margin lift, and a richer earnings profile all sit at the core of this narrative, with a future profit multiple that assumes Axsome Therapeutics can support a far larger CNS franchise than today.

Result: Fair Value of $276.47 (UNDERVALUED)

However, there is still meaningful execution risk if Auvelity or Sunosi underperform expectations, or if higher selling and R&D costs keep Axsome Therapeutics’ margins under pressure.

Another View: What Axsome Therapeutics’ P/S Ratio Is Telling You

The earlier fair value work suggests Axsome Therapeutics is trading below an estimated worth, but the current P/S ratio of 17.8x tells a more demanding story. It sits well above the US Pharmaceuticals average of 6.7x and the peer average of 10.4x, even if it is close to the 18.3x fair ratio.

In practice, that means the market already prices in strong revenue growth and execution, leaving less room for disappointment. If growth or margins fall short of what current multiples imply, how much downside are you comfortable underwriting at today’s levels?

Next Steps

With Axsome Therapeutics attracting strong opinions on both upside and risk, this is a moment to move quickly and pressure test the assumptions yourself using the 2 key rewards.

Looking for more investment ideas beyond Axsome Therapeutics?

Do not stop with Axsome Therapeutics alone. Broaden your watchlist with fresh stock ideas that match your risk tolerance and income goals using focused screeners.

• Target potential upside in overlooked corners of the market by checking companies highlighted in our screener containing 19 high quality undiscovered gems.
• Prioritize resilience and peace of mind by reviewing companies flagged in our 72 resilient stocks with low risk scores.
• Strengthen the quality of your portfolio by scanning financially healthier companies through our solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.